Long-acting muscarinic antagonists

References

• Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2013. Available from: www.goldcopd.org/uploads/users/files/GOLD_Report_2013_Feb20.pdf [Last accessed 31th December 2014]
   Google Scholar
• Singh D, Magnussen H, Kirsten A, et al. A randomized, placebo- and active-controlled dose-finding study of aclidinium bromide administered twice-daily in COPD patients. Pulm Pharmacol Ther 2012;25(3):248-53
   PubMed Web of Science ®Google Scholar
• Mete A, Bowers K, Chevalier E, et al. The discovery of AZD9164, a novel muscarinic M3 antagonist. Bioorg Med Chem Lett 2011;21(24):7440-6
   PubMed Web of Science ®Google Scholar
• Abrahams R, Moroni-Zentgraf P, Ramsdell J, et al. Safety and efficacy of the once-daily anticholinergic BEA2180 compared with tiotropium in patients with COPD. Respir Med 2013;107(6):854-62
   Google Scholar
• Beier J, van Noord J, Deans A, et al. Safety and efficacy of dual therapy with GSK233705 and salmeterol versus monotherapy with salmeterol, tiotropium, or placebo in a crossover pilot trial study in partially reversible COPD patients. Int J COPD 2012;7:153-64
   Google Scholar
• Arievich H, Overend T, Renard D, et al. A novel model-based approach for dose determination of glycopyrronium bromide in COPD. BMC Pulm Med 2012;12:74
   PubMed Web of Science ®Google Scholar
• Villetti G, Pastore F, Bergamaschi M, et al. Bronchodilator activity of (3R)-3-[[[(3-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino] carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-1-azoniabicyclo[2.2.2]octane bromide (CHF5407), a potent, long-acting, and selective muscarinic M3 receptor antagonist. J Pharmacol Exp Ther 2010;335(3):622-35
   PubMed Web of Science ®Google Scholar
• Leaker BR, Barnes PJ, Jones CR, et al. Efficacy and safety of nebulised glycopyrrolate for administration using high efficiency nebuliser in patients with COPD. Br J Clin Pharmacol 2015;79(3):492-500
   PubMed Web of Science ®Google Scholar
• Rennard S, Fogarty C, Reisner C, et al. Randomized study of the safety, pharmacokinetics, and bronchodilatory efficacy of a proprietary glycopyrronium metered-dose inhaler in study patients with chronic obstructive pulmonary disease. BMC Pulm Med 2014;14:118
   PubMed Web of Science ®Google Scholar
• Pulido-Rios MT, McNamara A, Obedencio GP, et al. In vivo pharmacological characterization of TD-4208, a novel lung-selective inhaled muscarinic antagonist with sustained bronchoprotective effect in experimental animal models. J Pharmacol Exp Ther 2013;346(2):241-50
   PubMed Web of Science ®Google Scholar
• Littner MR, Ilowite JS, Tashkin DP, et al. Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161(4 Pt 1):1136-42
   PubMed Web of Science ®Google Scholar
• van Noord JA, Cornelissen PJ, Aumann JL, et al. The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients. Respir Med 2009;103(1):22-9
   PubMed Web of Science ®Google Scholar
• Brashier B, Dhembare P, Jantikar A, et al. Tiotropium administered by a pressurized metered dose inhaler (pMDI) and spacer produces a similar bronchodilator response as that administered by a Rotahaler in adult subjects with stable moderate-to-severe COPD. Respir Med 2007;101(12):2464-71
   PubMed Web of Science ®Google Scholar
• Decramer M, Maltais F, Feldman G, et al. Bronchodilation of umeclidinium, a new long-acting muscarinic antagonist, in COPD patients. Respir Physiol Neurobiol 2013;185:393-9
   PubMed Web of Science ®Google Scholar
• D’Urzo A, Rennard S, Kerwin E, et al. on behalf of the AUGMENT COPD Study Investigators. Efficacy and safety of a fixed-dose combination of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study. Respir Res 2014;15:123
   PubMed Web of Science ®Google Scholar
• Bateman E, Ferguson GT, Barnes N, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J 2013;42(6):1484-94
   PubMed Web of Science ®Google Scholar
• Salvi S, Brashier B, Gothi D, et al. Bronchodilator efficacy of tiotropium-formoterol via single pressurized metered dose inhaler (pMDI) versus tiotropium alone in COPD. Pulm Pharmacol Ther 2014;27(1):90-5
   PubMed Web of Science ®Google Scholar
• Buhl R, Maltais F, Abrahams R, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4). Eur Respir J 2015;45(4):969-79
   PubMed Web of Science ®Google Scholar
• Donohue JF, Maleki-Yazdi MR, Kilbride S, et al. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med 2013;107(10):1538-46
   PubMed Web of Science ®Google Scholar
• Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002;19(2):217-24
   PubMed Web of Science ®Google Scholar
• Vincken W, van Noord JA, Greefhorst APM, et al. on behalf of the Dutch/Belgian Tiotropium Study Group. Improved health outcomes in patients with COPD during 1 yr’s treatment with tiotropium. Eur Respir J 2002;19(2):209-16
   PubMed Web of Science ®Google Scholar
• Chan CK, Maltais F, Sigouin C, et al. A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease. Can Respir J 2007;14(8):465-72
   Google Scholar
• Cazzola M, Andò F, Santus P, et al. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD. Pulm Pharmacol Ther 2007;20(5):556-61
   PubMed Web of Science ®Google Scholar
• Freeman D, Lee A, Price D. Efficacy and safety of tiotropium in COPD patients in primary care-the SPiRiva Usual CarE (SPRUCE) study. Respir Res 2007;8:45
   PubMed Web of Science ®Google Scholar
• Criner GJ, Sharafkhaneh A, Player R, et al. Efficacy of tiotropium inhalation powder in african-american patients with chronic obstructive pulmonary disease. COPD 2008;5:35-41
   PubMedGoogle Scholar
• Moita J, Bárbara C, Cardoso J, et al. Tiotropium improves FEV1 in patients with COPD irrespective of smoking status. Pulm Pharmacol Ther 2008;21:146-51
   PubMed Web of Science ®Google Scholar
• Voshaar T, Lapidus R, Maleki-Yazdi R, et al. A randomized study of tiotropium Respimat Soft Mist Inhaler vs ipratropium pMDI in COPD. Respir Med 2008;102:32-341
   PubMed Web of Science ®Google Scholar
• Niewoehner DE, Rice K, Cote C, et al. Therapeutic conversion of ipratropium and albuterol to tiotropium in patients with chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2009;22:587-92
   Google Scholar
• Welte T, Miravitlles M, Hernandez P, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;180(8):741-50
   PubMed Web of Science ®Google Scholar
• Bateman ED, Tashkin D, Siafakas N, et al. A one-year trial of tiotropium Respimat plus usual therapy in COPD patients. Respir Med 2010;104:1460-72
   PubMed Web of Science ®Google Scholar
• Bateman E, Singh D, Smith D, et al. Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies. Int J Chronic Obstructive Pulm Dis 2010;5:197-208
   PubMedGoogle Scholar
• Chanez P, Burge PS, Dahl R, et al. Aclidinium bromide provides long-acting bronchodilation in patients with COPD. Pulm Pharmacol Ther 2010;23:15-21
   PubMed Web of Science ®Google Scholar
• Donohue JF, Fogarty C, Lötvall J, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010;182:155-62
   PubMed Web of Science ®Google Scholar
• Ichinose M, Fujimoto T, Fukuchi Y. Tiotropium 5 microg via Respimat and 18 microg via HandiHaler: efficacy and safety in Japanese COPD patients. Respir Med 2010;104:2-228-36
   Google Scholar
• Buhl R, Dunn LJ, Disdier C, et al. Blinded 12- week comparison of once-daily indacaterol and tiotropium in COPD. Eur Respir J 2011;38(4):797-803
   PubMed Web of Science ®Google Scholar
• D’Urzo A, Ferguson GT, van Noord JA, et al. Efficacy and safety of once-daily NVA237 in patients with moderate to severe COPD: the GLOW1 trial. Respir Res 2011;12:156
   PubMed Web of Science ®Google Scholar
• Jones PW, Rennard SI, Agusti A, et al. Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease. Respir Res 2011;12:55
   PubMed Web of Science ®Google Scholar
• Aalbers R, Maleki-Yazdi MR, Hamilton A, et al. Dose-finding study for tiotropium and olodaterol when administered in combination via the Respimat inhaler in patients with COPD. Eur Respir J 2012;36(Suppl 56):P2882A
   Google Scholar
• Hanania NA, Crater GD, Morris AN, et al. Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respir Med 2012;106:91-101
   PubMed Web of Science ®Google Scholar
• Jones PW, Singh D, Bateman ED, et al. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J 2012;40:830-6
   PubMed Web of Science ®Google Scholar
• Jung KS, Park HY, Park SY, et al. on behalf of Korean Academy of Tuberculosis and Respiratory Diseases study group; Korea Chronic Obstructive Pulmonary Disease study group. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Respir Med 2012;106(3):382-9
   PubMed Web of Science ®Google Scholar
• Kerwin EM, D’Urzo AD, Gelb AF, et al. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD 1). COPD 2012;9:90-101
   PubMedGoogle Scholar
• Kerwin E, Hébert J, Gallagher N, et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with moderate-to-severe COPD over 52 weeks: The GLOW2 study. Eur Respir J 2012;40:1106-14
   PubMed Web of Science ®Google Scholar
• Dahl R, Jadayel D, Alagappan VKT, et al. Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study. Int J Chronic Obstruct Pulm Dis 2013;8:501-8
   PubMed Web of Science ®Google Scholar
• Decramer ML, Chapman KR, Dahl R, et al. on behalf of the INVIGORATE investigators. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir Med 2013;1(7):524-33
   PubMed Web of Science ®Google Scholar
• Rennard SI, Scanlon PD, Ferguson GT, et al. ACCORD COPD II: a randomized clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clin Drug Investig 2013;33(12):893-904
   PubMed Web of Science ®Google Scholar
• Celli B, Crater G, Kilbride S, et al. Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study. Chest 2014;145(5):981-91
   PubMed Web of Science ®Google Scholar
• Chapman KR, Beeh K-M, Beier J, et al. A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study. BMC Pulm Med 2014;14:4
   PubMed Web of Science ®Google Scholar
• Decramer M, Anzueto A, Kerwin E, et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med 2014;2(6):472-86
   PubMed Web of Science ®Google Scholar
• Frith P, Ratnavadivel R. Thompson P, et al for the GLISTEN Study. Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study – a randomised controlled trial. Thorax 2015;70:519-27
   PubMed Web of Science ®Google Scholar
• Maleki-Yazdi MR, Kaelin T, Richard N, et al. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial. Respir Med 2014;108:1752-60
   PubMed Web of Science ®Google Scholar
• Maltais F, Singh S, Donald AC, et al. Effects of a combination of umeclidinium/vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: two randomized, double-blind clinical trials. Ther Adv Respir Dis 2014;8(6):169-81
   PubMed Web of Science ®Google Scholar
• Singh D, Jones PW, Bateman ED, et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomized study. BMC Pulm Med 2014;14:178
   PubMed Web of Science ®Google Scholar
• Trivedi R, Richard N, Mehta R, Church A. Umeclidinium in patients with COPD: a randomised, placebo-controlled study. Eur Respir J 2014;43:72-81
   PubMed Web of Science ®Google Scholar
• Vincken W, Aumann J, Chen H, et al. Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study. Int J COPD 2014;9:215-28
   Google Scholar
• Zhong N, Wang C, Zhou X, et al. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD. Int J COPD 2015;10:1015-26
   Google Scholar
• Zu Wallack R, Allen L, Hernandez G, et al. Efficacy and safety of combining olodaterol Respimat and tiotropium HandiHaler in patients with COPD: results of two randomized, double-blind, active-controlled studies. Int J Chron Obstruct Pulm Dis 2014;9:1133-44
   Google Scholar
• Wang C, Sun T, Huang Y, et al. Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study. Int J Chron Obstruct Pulmon Dis 2015;10:57-68
   PubMed Web of Science ®Google Scholar
• Calverley PM, Lee A, Towse L, et al. Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease. Thorax 2003;58:855-60
   PubMed Web of Science ®Google Scholar
• Celli B, ZuWallack R, Wang S, Kesten S. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 2003;124(5):1743-8
   PubMed Web of Science ®Google Scholar
• Briggs DDJr, Covelli H, Lapidus R, et al. Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD. Pulm Pharmacol Ther 2005;18(6):397-404
   PubMed Web of Science ®Google Scholar
• van Noord JA, Aumann JL, Janssens E, et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005;26(2):214-22
   PubMed Web of Science ®Google Scholar
• Dusser D, Bravo ML, Iacono P. The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur Respir J 2006;27(3):547-55
   PubMed Web of Science ®Google Scholar
• Verkindre C, Bart F, Aguilaniu B, et al. The effect of tiotropium on hyperinflation and exercise capacity in chronic obstructive pulmonary disease. Respiration 2006;73(4):420-7
   PubMed Web of Science ®Google Scholar
• Johansson G, Lindberg A, Romberg K, et al. Bronchodilator efficacy of tiotropium in patients with mild to moderate COPD. Pr Care Respir J 2008;17(3):169-75
   PubMedGoogle Scholar
• Magnussen H, Bugnas B, van Noord J, et al. Improvements with tiotropium in COPD patients with concomitant asthma. Respir Med 2008;102(1):50-6
   PubMed Web of Science ®Google Scholar
• Rabe F, Timmer W, Sagkriotis A, Viel K. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest 2008;134(2):225-62
   Google Scholar
• Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359(15):1543-54
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Littner M, Andrews CP, et al. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial. Respir Med 2008;102(4):479-87
   PubMed Web of Science ®Google Scholar
• Vogelmeier C, Kardos P, Harari S, et al. Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir Med 2008;102:1511-20
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Pearle J, Iezzoni D, Varghese ST. Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD 2009;6(1):17-22
   PubMedGoogle Scholar
• van Noord JA, Aumann JL, Janssens E, et al. Combining tiotropium and salmeterol in COPD: Effects on airflow obstruction and symptoms. Respir Med 2010;104(7):955-1004
   Google Scholar
• Magnussen H, Paggiaro P, Schmidt H, et al. Effect of combination treatment on lung volumes and exercise endurance time in COPD. Respir Med 2012;106:1413-20
   PubMed Web of Science ®Google Scholar
• Mahler D, D’Urzo A, Bateman ED, et al. on behalf of the INTRUST-1 and INTRUST-2 study investigators. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison. Thorax 2012;67(9):781-8
   PubMed Web of Science ®Google Scholar
• Beier J, Kirsten A-M, Mroz R, et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstrucive pulmonary diseas: results from a 6-week, randomized, controlled phase IIIb study. COPD 2013;10:511-22
   PubMedGoogle Scholar
• Vogelmeier CF, Bateman ED, Pallante J, et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med 2013;1(1):51-60
   PubMed Web of Science ®Google Scholar
• Casaburi R, Maltais F, Porszasz J; for the 205.440 Study Investigators. Effects of tiotropium on hyperinflation and treadmill exercise tolerance in mild to moderate chronic obstructive pulmonary disease. Ann Am Thorac Soc 2014;11(9):1351-61
   PubMedGoogle Scholar
• Lange P, Aumann J-L, Hamilton A, et al. The 24 hour lung function time profile of olodaterol once daily versus placebo and tiotropium in patients with moderate to very severe chronic obstructive pulmonary disease. J Pulm Respir Med 2014;4:4
   Google Scholar
• Singh D, Worsley S, Zhu CQ, et al. Umeclidinium/vilaterol (UMEC/VIL) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations. Eur Respir J 2014;44(Suppl 58):P290
   Google Scholar
• Troosters T, Sciurba FC, Decramer M, et al. Tiotropium in patients with moderate COPD naïve to maintenance therapy: a randomized placebo-controlled trial. NPJ Prim Care Respir J 2014;24:14003
   PubMed Web of Science ®Google Scholar
• Beeh K-M, Westerman J, Kirsten A-M, et al. The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2015. in press Available from: http://dx.doi.org/10.1016/j.pupt.2015.04.002
   Google Scholar
• Donohue JF, Worsley S, Zhu C_Q, et al. Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. Respir Med 2015;109(7):870-81
   Google Scholar
• Brusasco V, Hodder R, Miravitlles M, et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003;58(5):399-404
   PubMed Web of Science ®Google Scholar
• McNicholas WT, Calverley PM, Lee A, Edwards JC. Tiotropium Sleep Study in COPD Investigators. Long-acting inhaled anticholinergic therapy improves sleeping oxygen saturation in COPD. Eur Respir J 2004;23(6):825-31
   PubMed Web of Science ®Google Scholar
• O’Donnell DE, Fluge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004;23:832-40
   PubMed Web of Science ®Google Scholar
• Casaburi R, Kukafka D, Cooper CB, et al. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 2005;127(3):809-17
   PubMed Web of Science ®Google Scholar
• Covelli H, Bhattacharya S, Cassino C, et al. Absence of electrocardiographic findings and improved function with once-daily tiotropium in patients with chronic obstructive pulmonary disease. Pharmacotherapy 2005;25(12 I):1708-18
   Google Scholar
• Maltais F, Hamilton A, Marciniuk D, et al. Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest 2005;128(3):1168-78
   PubMed Web of Science ®Google Scholar
• Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 2005;143:317-26
   PubMed Web of Science ®Google Scholar
• Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007;146(8):545-55
   PubMed Web of Science ®Google Scholar
• Powrie DJ, Wilkinson TM, Donaldson GC, et al. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. Eur Respir J 2007;30:472-8
   PubMed Web of Science ®Google Scholar
• Ambrosino N, Foglio K, Balzano G, et al. Tiotropium and exercise training in COPD patients: Effects on dyspnea and exercise tolerance. Int J Chron Obstruct Pulmon Dis 2008;3(8):771-80
   Google Scholar
• Tonnel AB, Perez T, Grosbois JM, et al. Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD. Int J Chron Obstruct Pulmon Dis 2008;3(2):301-10
   PubMedGoogle Scholar
• Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone or tiotropium bromide. Am J Respir Crit Care Med 2008;177:19-26
   PubMed Web of Science ®Google Scholar
• Perng DW, Tao CW, Su KC, et al. Anti-inflammatory effects of salmeterol/fluticasone, tiotropium/fluticasone or tiotropium in COPD. Eur Respir J 2009;33(4):778-84
   Google Scholar
• Vogelmeier C, Verkindre C, Cheung D, et al. Safety and tolerability of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients. Pulm Pharmacol Ther 2010;23:438-44
   PubMed Web of Science ®Google Scholar
• Maltais F, Celli B, Casaburi R, et al. Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respir Med 2011;105:580-7
   PubMed Web of Science ®Google Scholar
• Vogelmeier C, Hederer B, Glaab T, et al. for the POET-COPD Investigators. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011;364:1093-103
   PubMed Web of Science ®Google Scholar
• Feldman G, Walker RR, Brooks J, et al. 28-day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trial. Pulm Pharmacol Ther 2012;25:465-71
   PubMed Web of Science ®Google Scholar
• Asai K, Minakata Y, Hirata K, et al. QVA149 once-daily is safe and well tolerated and improves lung function and health status in Japanese patients with COPD: the ARISE study. Eur Respir J 2013;42(Suppl 57):P3392
   Google Scholar
• Cooper CB, Celli BR, Jardim JR, et al. Treadmill endurance during 2-year treatment with tiotropium in patients with COPD: a randomized trial. Chest 2013;144(2):490-7
   PubMed Web of Science ®Google Scholar
• Dahl R, Chapman KR, Rudolf M, et al. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study. Respir Med 2013;107(10):1558-67
   PubMed Web of Science ®Google Scholar
• Gelb AF, Tashkin DP, Make BJ, et al. on behalf of the LAS-MD-35 study investigators. Long-term safety and efficacy of twice-daily aclidinium bromide in patients with COPD. Respir Med 2013;107(12):1957-65
   PubMed Web of Science ®Google Scholar
• Maltais F, Mahler DA, Pepin V, et al. Effect of fluticasone propionate/salmeterol plus tiotropium versus tiotropium on walking endurance in COPD. Eur Respir J 2013;42(2):539-41
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med 2013;1(3):199-209
   PubMed Web of Science ®Google Scholar
• Wise RA, Anzueto A, Cotton D, et al. on behalf of the TIOSPIR Investigators. Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med 2013;369(16):1491-501
   PubMed Web of Science ®Google Scholar
• Donohue JF, Niewoehner D, Brooks J, et al. Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study. Respir Res 2014;15:78
   PubMed Web of Science ®Google Scholar
• Mahler DA, Decramer M, D’Urzo A, et al. Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study. Eur Respir J 2014;43(6):1599-609
   PubMed Web of Science ®Google Scholar
• Make B, Donohue JF, Zhong X, et al. Long-term safety of a fixed-dose combination of aclidinium bromide/formoterol fumarate in patients with stable moderate to severe COPD. Chest 2014;145(3):A386
   Google Scholar
• Buhl R, Gessner C, Schuermann W, et al. Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study. Thorax 2015;70(4):311-19
   PubMedGoogle Scholar
• Hohlfeld JM, Sharma A, van Noord JA, et al. Pharmacokinetics and pharmacodynamics of tiotropium solution and tiotropium powder in chronic obstructive pulmonary disease. J Clin Pharmacol 2014;54(4):405-14
   PubMed Web of Science ®Google Scholar
• Donohue JF, Kalberg C, Shah P, et al. Dose response of umeclidinium administered once or twice daily in patients with COPD: A pooled analysis of two randomized, double-blind, placebo-controlled studies. J Clin Pharmacol 2014;54(11):1214-20
   PubMed Web of Science ®Google Scholar
• Karner C, Chong J, Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012;7:CD009285
   PubMed Web of Science ®Google Scholar
• Beeh KM, Singh D, Di Scala L, Drollmann A. Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. Int J Chron Obstruct Pulmon Dis 2012;7:503-13
   PubMed Web of Science ®Google Scholar
• Beeh KM, Watz H, Puente-Maestu L, et al. Aclidinium improves exercise endurance, dyspnea, lung hyperinflation, and physical activity in patients with COPD: a randomized, placebo-controlled, cross-over trial. BMC Pulm Med 2014;14:209
   PubMed Web of Science ®Google Scholar
• Beeh K-M, Korn S, Beier J, et al. Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study. Respir Med 2014;108(4):584-92
   PubMed Web of Science ®Google Scholar
• Liu Y, Shi H, Sun X, et al. Benefits of adding fluticasone propionate/salmeterol to tiotropium in COPD: a meta-analysis. Eur J Intern Med 2014;25:491-5
   Google Scholar
• Mathioudakis AG, Kanavidis P, Chatzimavridou-Grigoriadou V, et al. Tiotropium HandiHaler improves the survival of patients with COPD: a systematic review and meta-analysis. J Aerosol Med Pulm Drug Deliv 2014;27(1):43-50
   Google Scholar
• Halpin DMG, Dahl R, Hallmann C, et al. Tiotropium Handihaler and Respimat in COPD: a pooled safety analysis. Int J Chron Obstruct Pulmon Dis 2015;10:239-59
   PubMed Web of Science ®Google Scholar
• Afonso AS, Verhamme KM, Stricker BH, et al. Inhaled anticholinergic drugs and risk of acute urinary retention. BJU Int 2011;107(8):1265-72
   Google Scholar
• Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008;300(12):1439-50
   PubMed Web of Science ®Google Scholar
• Dong YH, Lin HH, Shau WY, et al. Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials. Thorax 2013;68(1):48-56
   PubMed Web of Science ®Google Scholar
• de Luise C, Lanes SF, Jacobsen J, et al. Cardiovascular and respiratory hospitalizations and mortality among users of tiotropium in Denmark. Eur J Epidemiol 2007;22(4):267-72
   PubMed Web of Science ®Google Scholar
• Ajmera M, Shen C, Pan X, et al. Inhaled anticholinergic use and all-cause mortality among elderly Medicare beneficiaries with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2013;8:298-4
   Google Scholar
• Short PM, Williamson PA, Elder DH, et al. The impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long-acting beta-agonist therapy in COPD. Chest 2012;141(1):81-6
   PubMed Web of Science ®Google Scholar
• Gershon A, Croxford R, To T, et al. Comparison of inhaled long-acting beta-agonist and anticholinergic effectiveness in older patients with chronic obstructive pulmonary disease. A coohort study. Ann Intern Med 2011;154:583-92
   PubMed Web of Science ®Google Scholar
• Verhamme KM, Afonso A, Romio S, et al. Use of tiotropium Respimat® SMI vs tiotropium Handihaler® and mortality in patients with COPD. Eur Respir J 2013;42(3):606-15
   Web of Science ®Google Scholar
• Rottenkolber M, Rottenkolber D, Fischer R, et al. Inhaled beta-2-agonists/muscarinic antagonists and acute myocardial infarction in COPD patients. Respir Med 2014;108(8):1075-90
   Google Scholar
• Schmid K, Pascual S, Garcia Gil E, et al. Pharmacokinetics and safety of aclidinium bromide, a muscarinic antagonist, in adults with normal or impaired renal function: a phase I, open-label, single-dose clinical trial. Clin Ther 2010;32:1798-812
   PubMed Web of Science ®Google Scholar
• Bartels C, Looby M, Sechaud R, Kaiser G. Determination of the pharmacokinetics of glycopyrronium in the lung using a population pharmacokinetic modelling approach. Br J Clin Pharmacol 2013;76(6):868-79
   PubMed Web of Science ®Google Scholar
• Goyal N, Beerahee M, Kalberg C, et al. Population pharmacokinetics of inhaled umeclidinium and vilanterol in patients with chronic obstructive pulmonary disease. Clin Pharmacokinetic 2014;53(7):637-48
   PubMed Web of Science ®Google Scholar
• Mehta R, Hardes K, Brealey N, et al. Effect of severe renal impairment on umeclidinium and umeclidinium/vilanterol pharmacokinetics and safety: a single-blind, nonrandomized study. Int J Chron Obstruct Pulmon Dis 2014;10:15-23
   PubMed Web of Science ®Google Scholar
• Mehta R, Hardes K, Kelleher D, et al. Effects of moderate hepatic impairment on the pharmacokinetic properties and tolerability of umeclidinium and vilanterol in inhalational umeclidinium monotherapy and umeclidinium/vilanterol combination therapy: an open-label, nonrandomized study. Clin Ther 2014;36(7):1016-27
   PubMed Web of Science ®Google Scholar
• Magnussen H, Watz H, Zimmermann I, et al. Peak inspiratory flow through the Genuair inhaler in patients with moderate or severe COPD. Respir Med 2009;103(12):1832-7
   PubMed Web of Science ®Google Scholar
• Chapman KR, Fogarty CM, Peckitt C, et al. on behalf of the INDEED study investigators. Delivery characteristics and patients’ handling of two single-dose dry-powder inhalers used in COPD. Int J Chron Obstruct Pulmon Dis 2011;6:353-63
   PubMed Web of Science ®Google Scholar
• Colthorpe P, Voshaar T, Kieckbusch T, et al. Delivery characteristics of a low-resistance dry-powder inhaler used to deliver the long-acting muscarinic antagonist glycopyrronium. J Drug Assess 2013;2:11-16
   PubMedGoogle Scholar
• Gjaltema D, Hagedoorn P, Grasmeijer F, et al. Comparative in vitro performance of the new drug aclidinium in a novel multidose dry powder inhaler. Eur Respir J 2013;42(Suppl57):P3384
   Google Scholar
• Ciciliani A-M, Wachtel H, Langguth P. Comparing Respimat® Soft Mist™ Inhaler and DPI aerosol deposition by combined in vitro measurements and CFD simulations. Respir Drug Deliver 2014;2:453
   Google Scholar
• Kruger P, Ehrlein B, Zier M, Greguletz R. Inspiratory flow resistance of marketed dry powder inhalers (DPI). Eur Respir J 2014;44(Suppl58):4635
   Google Scholar
• Al-Showair RA, Tarsin WY, Assi KH, et al. Can all patients with COPD use the correct inhalation flow with all inhalers and does training help? Respir Med 2007;101(11):2395-401
   PubMed Web of Science ®Google Scholar
• Bruscoli R, De Bernardo T, Bracci LS, et al. Acute exacerbation of severe COPD may cause misuse using HandiHaler®. Rassegna di Patologia dell’Apparato Respiratorio 2009;24:375-9
   Google Scholar
• Dahl R, Backer V, Ollgaard B, et al. Assessment of patient performance of the HandiHaler compared with the metered dose inhaler four weeks after instruction. Respir Med 2003;97(10):1126-33
   Google Scholar
• Moore AC, Stone S. Meeting the needs of patients with COPD: patients’ preference for the Diskus inhaler compared with the Handihaler. Int J Clin Pract 2004;58(5):444-50
   Google Scholar
• Schurmann W, Schmidtmann S, Moroni M, et al. Respimat Soft Mist Inhaler versus hydrofluoroalkane metered dose inhaler:patient preference and satisfaction. Treat Respir Med 2005;4:53-61
   PubMedGoogle Scholar
• Freytag F, Rau-Berger H, Glaab T, Wolf K. Respimat Soft Mist Inhaler preferred to Diskus by patients with COPD and/or asthma. Am J Respir Crit Care Med 2007;175:A639
   Google Scholar
• Van Der Palen J, Eijsvogel MM, Kuipers BF, et al. Comparison of the Diskus inhaler and the Handihaler regarding preference and ease of use. J Aerosol Med 2007;20(1):38-44
   PubMedGoogle Scholar
• Wilson DS, Gillion MS, Rees PJ. Use of dry powder inhalers in COPD. Int J Clin Pract 2007;61(12):2005-8
   PubMed Web of Science ®Google Scholar
• Hodder R, Reese PR, Slaton T. Asthma patients prefer Respimat Soft Mist Inhaler to Turbuhaler. Int J Chron Obstruct Pulmon Dis 2009;4:225-32
   PubMedGoogle Scholar
• Hass C, Engdahl K, Albert W, et al. Patient preferences and perceived ease of use in inhaler features: genuair vs other inhalers. Chest 2010;138:484A
   Google Scholar
• Fuhr R, Magnussen H, Singh D, et al. Patient assessments of ease of use of Genuair® versus Aerolizer® and HandiHaler®. Eur Respir J 2011;38(Suppl55):3979P
   Google Scholar
• Asakura Y, Nishimura N, Maezawa K, et al. Effect of switching tiotropium HandiHaler® to Respimat® Soft Mist™ Inhaler in patients with COPD: the difference of adverse events and usability between inhaler devices. J Aerosol Med Pulm Drug Deliv 2013;26(1):41-5
   Google Scholar
• Svedsater H, Dale P, Garrill K, et al. Qualitative assessment of attributes and ease of use of the Ellipta dry powder inhaler for delivery of maintenance therapy for asthma and COPD. BMC Pulm Med 2013;13:72
   PubMed Web of Science ®Google Scholar
• van der Palen J, Ginko T, Kroker A, et al. Preference, satisfaction and errors with two dry powder inhalers in patients with COPD. Expert Opin Drug Deliv 2013;10(8):1023-31
   PubMed Web of Science ®Google Scholar
• Komase Y, Asako A, Kobayashi A, Sharma R. Ease-of-use preference for the ELLIPTA® dry powder inhaler over a commonly used single-dose capsule dry powder inhaler by inhalation device-naïve Japanese volunteers aged 40 years or older. Int J Chron Obstruct Pulmon Dis 2014;9:1365-75
   PubMed Web of Science ®Google Scholar
• Sharma R, Komase Y, Akimoto A, Kobayashi A. Operability of the Ellipta dry powder inhaler: a comparative evaluation of handling technique in inhalation therapy-naive subjects. Am J Respir Crit Care Med 2014;189:A5693
   Google Scholar
• Pascual S, Feimer J, De Soyza A, et al. Preference, satisfaction and critical errors with Genuair and Breezhaler inhalers in patients with COPD: a randomised, cross-over, multicentre study. NPJ Prim Care Respir Med 2015;25:15018
   PubMed Web of Science ®Google Scholar
• Hanada S, Wada S, Ohno T, et al. Questionnaire on switching from the tiotropium HandiHaler to the Respimat inhaler in patients with chronic obstructive pulmonary disease: changes in handling and preferences immediately and several years after the switch. Int J Chron Obstruct Pulmon Dis 2015;10:69-77
   PubMed Web of Science ®Google Scholar
• Kuttler A, Dimke T. A novel biophysical simulation model of drug deposition implemented to predict and optimize QVA149 delivery to the lungs. Am J Respir Crit Care Med 2014;189:A3038
   Google Scholar
• Price D, West D, Brusselle G, et al. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns. Int J Chron Obstruct Pulmon Dis 2014;9:889-904
   PubMed Web of Science ®Google Scholar
• Antonelli Incalzi R, Corsonello A, Pedone C, et al. on behalf of the Extrapulmonary Consequences of COPD in the Elderly Study Investigators. Chronic renal failure. A neglected comorbidity of COPD. Chest 2010;137(4):831-7
   Google Scholar
• Ismaila A, Corriveau D, Vaillancourt J, et al. Impact of adherence to treatment with tiotropium and fluticasone propionate/salmeterol in chronic obstructive pulmonary diseases patients. Curr Med Res Opin 2014;30(7):1427-36
   PubMed Web of Science ®Google Scholar
• Cazzola M, Brusasco V, Centanni S, et al. PriMo:sharing principels and practices of bronchodilator therapy monitoring in COPD: a consensus intiative for optimizing therapeutic appropriateness among Italian specialists. Pulm Pharmacol ther 2013;26:218-28
   PubMed Web of Science ®Google Scholar
• Decramer M, Celli B, Kesten S, et al. on behalf of the UPLIFT investigators. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009;374(9696):1171-8
   PubMed Web of Science ®Google Scholar
• Hurst JR, Vestbo J, Anzueto A, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363(12):1128-38
   PubMed Web of Science ®Google Scholar
• Di Marco F, Verga M, Santus P, et al. Effect of formoterol, tiotropium, and their combination in patients with acute exacerbation of chronic obstructive pulmonary disease: a pilot study. Respir Med 2006;100(11):1925-32
   PubMed Web of Science ®Google Scholar
• Drescher GS, Carnathan BJ, Imus S, Colice GL. Incorporating tiotropium into a respiratory therapist-directed bronchodilator protocol for managing in-patients with COPD exacerbations decreases bronchodilator costs. Respir Care 2008;53(12):1678-84
   Google Scholar
• A Single-dose Study to Investigate the Effects of 4 Different Doses of Inhaled AZD8683 n Chronic Obstructive Pulmonary Disease (COPD) Patients. Available from: https://clinicaltrials.gov/ct2/show/NCT01708057
   Google Scholar
• To Compare the Pharmacokinetics of Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease (COPD). Available from: https://clinicaltrials.gov/ct2/show/NCT01785433
   Google Scholar
• Safety, Preliminary Pharmacokinetics and Bronchodilator Properties of V0162. Available from: https://clinicaltrials.gov/ct2/show/NCT01348555
   Google Scholar
• Glycopyrronium and Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) Dose Indicator Study in Adults With Moderate to Very Severe COPD. Available from: https://clinicaltrials.gov/ct2/show/NCT02268396
   Google Scholar
• Phase I Study Evaluating the Safety and Pharmacokinetics of Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (BGF MDI) in Healthy Volunteers. Available from: https://clinicaltrials.gov/ct2/show/NCT01980615
   Google Scholar
• Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2). Available from: https://clinicaltrials.gov/ct2/show/NCT01854658
   Google Scholar
• Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1). Available from: https://clinicaltrials.gov/ct2/show/NCT01854645
   Google Scholar
• PT003 MDI Dose Confirmation Study. Available from: https://clinicaltrials.gov/ct2/show/NCT01349816
   Google Scholar
• Glycopyrrolate/Formoterol Fumarate MDI Compared With Spiriva® as An Active Control in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease. Available from: https://clinicaltrials.gov/ct2/show/NCT01587079
   Google Scholar
• Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD). Available from: https://clinicaltrials.gov/ct2/show/NCT01085045
   Google Scholar
• Study to Evaluate Single Inhaled Doses of PT001, PT003, PT005 and PT001 Plus PT005 in Healthy Subjects. Available from: https://clinicaltrials.gov/ct2/show/NCT00893971
   Google Scholar
• Pharmacokinetic Study in Healthy Volunteers to Characterise the Exposure of Fluticasone Furoate (FF), Vilanterol (VI) and Umeclidinium (UMEC) at Two Different Doses. Available from: https://clinicaltrials.gov/ct2/show/NCT01894386
   Google Scholar
• A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD). Available from: https://clinicaltrials.gov/ct2/show/NCT02164513
   Google Scholar
• A Study to Assess the Systemic Exposure, Systemic Pharmacodynamics and Safety and Tolerability of FluticasoneFuroate, Umeclidinium and Vilanterol in Healthy Subjects. Available from: https://clinicaltrials.gov/ct2/show/NCT01691547
   Google Scholar
• A Study to Investigate the Pharmacokinetics, Safety and Tolerability of CHF 5993 pMDI in Subjects With Renal Impairment. (TRIPLE10). Available from: https://clinicaltrials.gov/ct2/show/NCT02040597
   Google Scholar
• Drug-drug Interaction Study of CHF5993 With Cimetidine. Available from: https://clinicaltrials.gov/ct2/show/NCT02287272
   Google Scholar
• Pharmacokinetics of CHF 5993 pMDI With and Without Spacer in COPD Patients (TRIPLE 4). Available from: https://clinicaltrials.gov/ct2/show/NCT02119234
   Google Scholar
• Efficacy of Fixed Combination of Beclomethasone + Formoterol + Glycopyrrolate Versus Foster® in Chronic Obstructive Pulmonary Diseases. Available from: https://clinicaltrials.gov/ct2/show/NCT01917331
   Google Scholar
• Phase II Study to Evaluate the Cardiac Safety of 2 Doses of CHF5993 Both Combined With CHF1535 BID Versus CHF1535 BID in Patients With Moderate to Severe COPD (CARSAF). Available from: https://clinicaltrials.gov/ct2/show/NCT01584505
   Google Scholar
• Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate in Chronic Obstructive Pulmonary Disease. Available from: https://clinicaltrials.gov/ct2/show/NCT01911364
   Google Scholar
• Phase I Study Evaluating the Safety and Pharmacokinetics of Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (BGF MDI) in Healthy Volunteers. Available from: https://clinicaltrials.gov/ct2/show/NCT01980615
   Google Scholar
• Pharmacokinetics and Safety Study of PT010 in Healthy Subjects. Available from: https://clinicaltrials.gov/ct2/show/NCT02189304
   Google Scholar
• Randomized, Crossover Safety and Pharmacokinetics Study of PT010. Available from: https://clinicaltrials.gov/ct2/show/NCT02197975
   Google Scholar